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In an evaluation of the API 20NE for the identification of Burkholderia spp., 792/800 (99%) Burkholderia
pseudomallei and 17/19 (89%) B. cepacia isolates were correctly identified but 10 B. mallei and 98 B. thailandensis
isolates were not correctly identified. A latex agglutination test was positive for 796/800 (99.5%) B. pseudomallei
isolates and negative for 120 other oxidase-positive gram-negative bacilli.
The gram-negative bacillus Burkholderia pseudomallei is a
category B biothreat agent and the cause of melioidosis. En-
demic infection is most common in northeast Thailand and
northern Australia, with endemic and imported melioidosis
being increasingly recognized around the world (2). When
diagnostic laboratory staff are familiar with B. pseudomallei,
basic screening tests (Gram stain, oxidase test, gentamicin and
polymyxin susceptibility, and colonial characteristics on a dif-
ferential agar medium) are inexpensive and accurate for the
identification of B. pseudomallei (3). Elsewhere, diagnostic lab-
oratories rely on kits or automated systems already in place for
the identification of other gram-negative bacilli. One kit used
worldwide for the identification of oxidase-positive gram-neg-
ative bacilli is the API 20NE (bioMe´rieux sa, Marcy l’Etoile,
France).
An evaluation of API 20NE for the identification of B.
pseudomallei was first reported in 1989; 390 of 400 (97.5%)
predominantly clinical B. pseudomallei isolates from patients in
Ubon Ratchathani, northeast Thailand, were correctly identi-
fied on first testing (3). A subsequent evaluation of API 20NE
using 103 B. pseudomallei isolates, the majority of which were
from cases of human disease in northern Australia, demon-
strated correct identification of 98% (10). Other studies, how-
ever, have reported poorer results. In an evaluation of 50
clinical B. pseudomallei isolates from Singapore, API 20NE
correctly identified 40 isolates, gave unacceptable or uninter-
pretable results for 4 isolates, and misidentified 6 isolates as
other species, the commonest being Chromobacterium viola-
ceum (7). Two further studies in 2005 reported correct identi-
fication of only 37% for 71 B. pseudomallei isolates from West-
ern Australia (8) and 60% of 58 B. pseudomallei isolates tested
at CDC, Atlanta, that were predominantly isolated from cases
of imported melioidosis (5).
One possible reason for the interstudy variability is that B.
pseudomallei isolates from different geographical areas are
phenotypically distinct and clinical isolates are distinct from
those from the environment. The first aim of this study was to
reexamine the accuracy of API 20NE using a large collection
(n  800) of B. pseudomallei isolates obtained from clinical
cases, the environment, and animals from seven Asian coun-
tries and northern Australia, together with 127 isolates repre-
senting other Burkholderia species.
Many investigators have reported the development of latex
agglutination tests for the identification of B. pseudomallei;
these have been evaluated using bacterial colonies growing on
solid agar or in liquid such as blood culture or urine (1, 4,
11–15, 17). The antibodies used to coat the latex beads have
varied and included polyclonal antibodies raised in rabbits (13,
14) and monoclonal antibody to exopolysaccharide (1, 12, 15,
17), lipopolysaccharide (4), or a 30-kDa antigen (11). These
have a high sensitivity and specificity overall, although not all
assays can distinguish between different species of Burkholderia
(including B. mallei and B. thailandensis). A commercial agglu-
tinating-antibody test has been evaluated; this correctly iden-
tified 82% of 71 isolates from Western Australia on first testing
(8). Our laboratory has previously described a latex agglutina-
tion test based on a monoclonal antibody to exopolysaccharide
(17). The second aim of this study was to determine its sensi-
tivity and specificity when applied to this large strain collection.
The study was undertaken at a single laboratory at the Well-
come Unit, Faculty of Tropical Medicine, Mahidol University, in
Bangkok, Thailand. The 927 Burkholderia sp. isolates tested were
identified by, and obtained from, multiple laboratories as de-
scribed in Table 1. An additional collection of 120 isolates repre-
senting a range of other oxidase-positive gram-negative species
were obtained from diagnostic laboratories in Thailand (Sappa-
sithiprasong Hospital in Ubon Ratchathani, Udon Thani General
Hospital, and The Neurology Institute, Bangkok) (Table 1). Bac-
terial identification was performed by the originating laboratory.
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These 120 isolates were used to assess the specificity of the latex
agglutination test. All isolates were stored at80°C in Trypticase
soy broth with 15% glycerol. Prior to testing, isolates were sub-
cultured twice on Columbia agar and incubated at 37°C in air for
18 to 24 h. Isolates were allocated a unique number in order to
blind the operator to the bacterial species and randomized to
ensure that all isolates were tested in random order.
API 20NE was performed as recommended by the manu-
facturer by technical staff with previous experience in its use.
The result for each test cupule was recorded as positive or
negative. API 20NE results were recorded by two independent
operators. In the event of a disagreement, a third person
checked for transcription errors; the API 20NE was repeated if
the result remained discrepant between the two operators.
Numerical profiles were interpreted using the APILAB Plus
software, version 1.21.
Latex beads coated with a monoclonal antibody specific to a
200-kDa exopolysaccharide of B. pseudomallei were prepared
as described previously (1, 17). The test was performed by
mixing bacterial cells picked from a single colony on Columbia
agar with 10 l of latex suspension on a glass slide. Agglutina-
tion was detected visually after rotation for 2 min. A positive
control (B. pseudomallei K96243) and negative control (Esch-
erichia coli ATCC 25922) were performed on each day the test
was used.
API 20NE correctly identified 792 of 800 (99.0%) isolates of
B. pseudomallei (sensitivity, 99.0%; 95% confidence interval
[CI], 98.0 to 99.6%) (Table 2). The remaining eight isolates
were misidentified as Chromobacterium violaceum (four isolates),
Burkholderia cepacia (two isolates), Pseudomonas aeruginosa (one
isolate), and Pseudomonas fluorescens (one isolate). All misidentifi-
cations were reproducible on repeat testing. Twenty-two profiles
were obtained (Table 2). The two most common profiles (1156576
for 453 isolates and 1156577 for 264 isolates) were different only for
citrate, while 1556576 (n 39) and 1556577 (n 10) were different
only for esculin hydrolysis. The two most common profiles
predominated in collections from each country. None of the 10
B. mallei isolates were correctly identified by API 20NE: 6 gave
an unacceptable profile, 2 were misidentified as Chromobacte-
rium violaceum, and 1 each was misidentified as Pseudomonas
aeruginosa and Pseudomonas alcaligenes. All 98 B. thailandensis
isolates were misidentified by API 20NE as follows: B. cepacia,
63 (64%); B. pseudomallei, 31 (32%); Pseudomonas fluorescens,
4 (4%). Of the B. cepacia isolates, 17 of 19 (89%) were cor-
rectly identified (2 with a low % identification of 66.7%) and 2
isolates were misidentified as Pseudomonas fluorescens. A dis-
crepant result occurred between the two readers on a single
occasion. This occurred due to a recording error rather than a
difference in opinion over interpretation of the API 20NE.
This suggests that a single experienced operator is sufficient to
interpret this test.
The latex agglutination test was positive for 796 of 800 B.
pseudomallei isolates (sensitivity, 99.5%; 95% CI, 98.7 to
99.9%). The four false negatives were reproducible on re-
peat testing. All four isolates were from Hong Kong (animal
strains) and were identified as a single clone (ST 70) on
multilocus sequence typing (16). There were no false posi-
tives among the 120 non-Burkholderia oxidase-positive con-
TABLE 1. Bacterial organisms used in this evaluation
Bacterial species (n) No. ofisolates Source Country(ies)
Burkholderia spp. (927)
B. pseudomallei (800) 450 Human Thailanda
86 Environment Thailandb
5 Human Cambodia
14 Environment Cambodia
58 Human Lao PDR
48 Environment Lao PDR
15 Environment Vietnam
11 Animal Malaysia
20 Human Singapore
23 Animal Hong Kong
3 Environment Hong Kong
45 Human Australia
17 Environment Australia
5 Animal Australia
B. mallei 10 Laboratory
strains
Various
B. thailandensis 98 Environment Thailand,
Cambodia,
and Vietnamc
B. cepacia 19 Laboratory
strains
Various
Oxidase-positive spp. (120)
Pseudomonas aeruginosa 86 Human Thailand
Pseudomonas spp. 9 Human Thailand
Stenotrophomonas maltophilia 3 Human Thailand
Achromobacter xylosoxidans 2 Human Thailand
Aeromonas spp. 20 Human Thailand
a Isolates were from Ubon Ratchathani (n  291), Udon Thani (100), Khon
Kaen (49), and Phangnga (10).
b Isolated in Ubon Ratchathani province.
c Eighty-six isolates were from Thailand, 3 were from Cambodia, and 9 were
from Vietnam.
TABLE 2. API 20NE profiles for 800 isolates of B. pseudomallei
Result (no. of isolates) Identity (%) Profile no. (no. of isolates identified)
B. pseudomallei (792) 80 1156576 (453), 1156577 (264), 1556576 (39), 1556577 (10), 1156477 (1), 1356577 (1),
1156574 (11), 1156575 (1), 0156576 (1), 1156556 (1), 1154576 (3), 1056576 (3),
1056577 (1)
80 1056574 (1), 1157576 (1), 1157577 (1)
Other species (8)
Chromobacterium violaceum 80 1150554 (1), 1150514 (2)
Chromobacterium violaceum 80 1156554 (1)
Burkholderia cepacia 80 1576576 (2)
Pseudomonas aeruginosa 80 1154554 (1)
Pseudomonas fluorescens 80 1156757 (1)
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trol organisms (specificity, 100%; 95% CI, 97.0 to 100%).
All 98 B. thailandensis isolates and all 19 B. cepacia isolates
were negative. However, 9 of 10 B. mallei isolates were
positive by latex agglutination, indicating that the test can-
not reliably differentiate between B. pseudomallei and B.
mallei.
Testing with the largest B. pseudomallei isolate collection
ever assessed by identification kits proved that API 20NE is
highly suitable for this purpose. It is unclear why the accuracy
of API 20NE for the identification of B. pseudomallei reported
by previous studies varied from 37% to 99% (3, 5, 7, 8, 10). We
did not find any evidence for segregation of biochemical pro-
files between different geographic areas. One possible reason
for this interstudy variability may lie with the interpretation of
assimilation tests, which can be difficult to read.
API 20NE is not suitable for the identification of B. thailan-
densis. This organism is usually nonpathogenic, reports of dis-
ease caused by this organism being limited to two cases (6, 9).
Incorrect identification of B. thailandensis as B. pseudomallei
could lead to treatment with a prolonged course of unneces-
sary antimicrobials, a possibility that should be born in mind in
geographic areas where both exist in the environment. In prac-
tice, B. thailandensis is rarely present in clinical specimens, but
alternative methods of identification are required if this species
is suspected.
All studies that utilize existing strain collections to assess the
accuracy of commonly used bacterial identification tools are
potentially biased since isolates are not a naive, untested bac-
terial population but have already been successfully identified.
The vast majority of the strains tested here have not been
identified previously using API 20NE, since identification of B.
pseudomallei in endemic areas commonly relies on a panel of
biochemical tests, including arabinose assimilation, together
with the susceptibility pattern.
The latex agglutination test was highly sensitive and specific
for the identification of B. pseudomallei, although it failed to
differentiate between this and B. mallei. The latex test is not
directly comparable to API 20NE since it does not provide an
alternative bacterial identification for negative isolates but
rather represents a cheap, easy-to-perform test in endemic
settings that regularly culture B. pseudomallei. Low-cost com-
mercial production could facilitate widespread access to this
useful reagent.
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